AtaGenix Laboratories

Home - About Us - Updates Center - News

Updates Center

  • AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
  • On August 13, 2025, BioTAG from Israel visited AtaGenix’s Wuhan headquarters to discuss antibody drug development, protein engineering, and CRO services. The collaboration aims to advance precision medicine and biopharmaceutical innovation globally.
  • AtaGenix will participate in LAB International 2025, taking place in Thailand from September 3 to 5, 2025. Visit Booth 2S21 to explore our capabilities in antibody discovery, engineering, protein expression, and purification, as well as the abinScience portfolio of recombinant proteins and antibodies. Let’s connect and discuss potential collaborations.
Messages